SanFran,

I have only seen the Resverlogix news release from 8/31/15 as well as the abstract for the mid-September EASD 2015 meeting that I've posted before. Other than that I haven't seen or heard anything else. I'm really hoping that once they start BETonMACE, that they will start publishing in scientific journals. It's nice that they are presenting at meetings via poster presentations or oral presentations, but these types of presentations only reach a limited audience and are not amenable to showing too much data, experimental design detail or thorough interpretation. Publishing in journals will reach a wider audience, allow for more data to be shown, allow for thorough description of study design and interpretations, and most importantly go through the rigors of the peer review process.

On that note, when will we hear about the start of BETonMACE? All we know right now is Fall 2015. Some count Fall as the beginning of September (today!). Others count it as the first Monday in September (Labor Day, September 7). Or is it around the autumnal equinox (September 23rd).

Lots going on in the next 4 weeks leading up to the September 30th annual meeting:

September 8-10: 17th Annual Global Investment Conference Rodman & Renshaw 2015 in New York. Resverlogix will present on September 10.

September 14-18: European Association for the Study of Diabetes in Stockholm, Sweden. Resverlogix is presenting an oral presentation on Friday September 18th at ~ 12PM (Sweden) entitled "RVX-208 acts via an epigenetic mechanism to lower Major Adverse Cardiovascular Events (MACE) in patients with atherosclerosis and especially in those with diabetes mellitus."

September 22-23: 3rd Annual Targeting Epigenetic Readers and Chromatin Remodelers: Advances in Bromodomain Drug Discovery and Development in Boston. Norman Wong will moderate a discussion group "Examining the Basic Actions of BET Proteins" on the afternoon ofSeptember 22 focusing on 1) Actions of BET proteins and specifically BRD4 in mediating actions of Pol II that differentiates it from BRD2/3 activity; 2) Actions of BET proteins in selective vs. pan inhibition; 3) Actions of BET proteins in inflammation. Then on September 23 at 10:55 AM (Boston) Norman Wong will present in a talk entitled "BET Proteins; Selective and Pan-Inhibition for Treating Human Diseases." Here is the description of the talk:

"Our studies of BET inhibitors began with compounds that selectively inhibited the activity of BD-2 for reduction of cardiovascular risks. The lead candidate has been tested in clinical trials involving almost 1000 patients enrolled in the various trials from phase 1a to 2b. Our studies have also expanded to scaffolds that are pan bromodomain inhibitors which appear to be useful other human diseases."

September 26: GCFF (Global Chinese Financial Forum) in Toronto. Don McCaffrey is giving the keynote speech (40 minute time slot starting at 9:30 AM) in the "Trend of Life Science Section". This is the first talk fo the morning for this one day event.That's all that they list on their events page for now.